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Abstract
Analyzing large-scale, multi-experiment studies
requires scientists to test each experimental out-
come for statistical significance and then assess
the results as a whole. We present Black Box
FDR (BB-FDR), an empirical-Bayes method for
analyzing multi-experiment studies when many
covariates are gathered per experiment. BB-FDR
learns a series of black box predictive models to
boost power and control the false discovery rate
(FDR) at two stages of study analysis. In Stage
1, it uses a deep neural network prior to report
which experiments yielded significant outcomes.
In Stage 2, a separate black box model of each
covariate is used to select features that have sig-
nificant predictive power across all experiments.
In benchmarks, BB-FDR outperforms competing
state-of-the-art methods in both stages of anal-
ysis. We apply BB-FDR to two real studies on
cancer drug efficacy. For both studies, BB-FDR
increases the proportion of significant outcomes
discovered and selects variables that reveal key
genomic drivers of drug sensitivity and resistance
in cancer.
1. Introduction
High-throughput screening (HTS) techniques have funda-
mentally changed the landscape of modern biological ex-
perimentation. Rather than conducting just one experiment
at a time, HTS enables scientists to perform hundreds of
parallel experiments, each with different biological sam-
ples and different interventions. At the same time, HTS
also enables scientists to gather rich contextual informa-
tion about each experiment by profiling the samples under
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study using techniques like DNA sequencing. Thus, each
HTS study produces a dataset of many experiments, where
each experiment contains both an outcome variable and a
high-dimensional feature set describing the context.
Figure 1 shows a slice of the Genomics of Drug Sensitivity
in Cancer (GDSC) dataset (Yang et al., 2012), an HTS study
investigating how cancer cell lines respond to different can-
cer therapeutics. The left panel shows the relative response
of 30 different cancer cell lines (C1, C2, . . . , C30) treated
with the drug Nutlin-3. For each cell line, the treatment re-
sponse (black triangles) is overlayed on top of the untreated
control replicate distribution (gray box plots). Even when no
drug is applied, each cell line still exhibits natural variation.
The first goal in analyzing this data is therefore to address
the question of whether a given cell line responded to the
treatment. Concretely, we need to perform a hypothesis test
for each cell line, where the null hypothesis is that the drug
had no effect. Absent other information, this would be a
classic multiple hypothesis testing (MHT) problem.
But HTS studies such as GDSC differ from the classical
setup by also producing a rich set of side information for
each experiment. The right panel of Figure 1 shows a subset
of the genomic profile for each cell line, with a black dot
indicating the cell line has a mutation in that gene. Bio-
logically, a mutated gene can lead to different phenotypic
behavior that may cause sensitivity or resistance to a drug.
Statistically, this means the likelihood of a cell line respond-
ing to treatment is a latent function of that cell line’s ge-
nomic profile. Identifying which mutations are associated
with treatment response could guide future experiments and
development of new targeted therapies. Deriving scientific
insight from patterns across experiments represents a second
phase of hypothesis testing, where the null hypothesis is
that a given gene is not associated with drug response.
We term these two phases Stage 1 and Stage 2 and ask two
scientifically-motivated statistical inference questions:
• Stage 1: How do we leverage the available side infor-
mation in a HTS study to increase how many significant
outcomes we can detect?
• Stage 2: Can we discover which variables are associ-
ated with significant outcomes, even when the underly-
ing function is high-dimensional and nonlinear?
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Figure 1. Left: a subset of 30 cell line experiments from the Nutlin-3 case study in Section 5. Control replicates (gray box plots) and cell
line responses (black triangles) are measured as z-scores relative to mean control values. Right: a subset of the corresponding genomic
features for each experiment; black dots indicate a cell line has a recurrent mutation in the gene labeled on the x-axis. The goal in Stage
1 analysis is to select cell lines that showed a significant response (circled in blue). In Stage 2, the genomic features are analyzed to
understand the mutations driving drug response (circled in orange).
We answer both of these questions and propose Black Box
FDR (BB-FDR), a method for analyzing multi-experiment
studies with many covariates gathered per experiment. BB-
FDR uses the covariates to build a deep probabilistic model
that predicts how likely a given experiment is to generate
significant outcomes a priori. It uses this prior model to
adaptively select significant outcomes in a manner that con-
trols the overall false discovery rate (FDR) at a specified
Stage 1 level. BB-FDR then builds a predictive model of
each covariate to perform variable selection on the Stage 1
model while conserving a specified Stage 2 FDR threshold.
We validate BB-FDR on both synthetic and real data. BB-
FDR outperforms other state-of-the-art Stage 1 methods
in a series of benchmarks, including the recently-proposed
NeuralFDR (Xia et al., 2017). BB-FDR is also a more
pragmatic choice compared to a fully-Bayesian approach:
it scales trivially to thousands of covariates, can learn ar-
bitrarily complex functions, and runs easily on a laptop.
We apply BB-FDR to a real-world case study of two cancer
drug screenings. BB-FDR finds more significant discoveries
on the data and recovers an informative set of biologically-
plausible genes that may convey drug sensitivity and resis-
tance in cancer.
2. Multiple testing and FDR control
In the classical MHT setup, z = (z1, . . . , zn) are a set of
independent observations of the outcomes of n experiments.
For each experiment, a treatment is applied to a target and
the treatment has either no effect (hi = 0) or some effect
(hi = 1). If the treatment has no effect, the distribution of
the test statistic is the null distribution f0(z); otherwise it
follows an unknown alternative distribution f1(z). The null
hypothesis for every experiment is that the test statistic was
drawn from the null distribution: H0 : hi = 0.
2.1. False discovery rate control
In most experiments of interest, it is impossible to determine
hi with no error. For a given prediction hˆi, we say it is
a true positive or a true discovery if hˆi = 1 = hi and
a false positive or false discovery if hˆi = 1 6= hi. Let
S = {i : hi = 1} be the set of observations for which the
treatment had an effect and Sˆ = {i : hˆi = 1} be the set of
predicted discoveries. We seek procedures that maximize
the true positive rate (TPR) also known as power, while
controlling the false discovery rate–the expected proportion
of the predicted discoveries that are actually false positives,
FDR := E[FDP] , FDP =
#{i : i ∈ Sˆ\S}
#{i : i ∈ Sˆ} . (1)
FDP in (1) is the false discovery proportion: the actual
proportion of false positives in the predicted discovery set
for a specific experiment. While ideally we would like to
control the FDP, the randomness of the outcome variables
makes this impossible in practice. Thus FDR is the typical
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Figure 2. The graphical model for BB-FDR.
error measure targeted in modern scientific analyses.
2.2. Related work
Controlling FDR in multiple hypothesis testing has a long
history in statistics and machine learning. The Benjamini-
Hochberg (BH) procedure (Benjamini & Hochberg, 1995)
is the classic technique and still the most widely used in
science. Many other methods have since been developed
to take advantage of study-specific information to increase
power. Recent examples include accumulation tests for
ordering information (Li & Barber, 2017), the p-filter for
grouping and test statistic dependency (Ramdas et al., 2017),
FDR smoothing for spatial testing (Tansey et al., 2017),
FDR-regression for low-dimensional covariates (Scott et al.,
2015), and, most recently, NeuralFDR for high-dimensional
covariates (Xia et al., 2017). We consider high-dimensional
covariates and compare against NeuralFDR in Section 4.
3. Black Box FDR
Consider a study with n independent experiments that pro-
duces a set of independent test statistics z = (z1, . . . , zn)
corresponding to the outcome measurements, as in Sec-
tion 2. However, now each experiment also has a vector of
m covariates Xi· = (Xi1, . . . , Xim) containing side infor-
mation that may influence the outcome of that experiment.
Specifically, whether the experiment comes from the null
distribution hi = 0 or the alternative hi = 1 is allowed to
depend arbitrarily on Xi·.
BB-FDR extends the empirical-Bayes two-groups model of
Efron (2008) by building a hierarchical probabilistic model
with experiment-specific priors modeled through a deep
neural network. We first estimate the alternative distribution
offline using predictive recursion (Newton, 2002) to estimate
f1. This follows other recent extensions to the two-groups
model (Scott et al., 2015; Tansey et al., 2017) and enjoys
strong empirical performance and consistency guarantees
(Tokdar et al., 2009). BB-FDR then focuses on modeling the
experiment-specific prior, assuming the null and alternative
distributions are fixed.
3.1. Stage 1: determining significant outcomes
We model the test statistic as arising from a mixture model
of two components, the null (f0) and the alternative (f1). An
experiment-specific weight ci then models the prior prob-
ability of the test statistic coming from the alternative (i.e.
the probability of the treatment having an effect a priori).
We place a beta prior on each experiment-specific prior ci
and model the parameters of the hyperprior with a black box
function G parameterized by θ; in our implementation, G is
a deep neural network. The complete model for BB-FDR is:
zi ∼ hif1(zi) + (1− hi)f0(zi)
hi ∼ Bernoulli(ci)
ci ∼ Beta(ai, bi)
ai, bi = Gθ,i(X) .
(2)
We optimize θ by integrating out hi and maximizing the
complete data log-likelihood,
pθ(zi) =
∫ 1
0
(cif1(zi)+(1−ci)f0(zi))Beta(ci|Gθ,i(X))dci .
(3)
Figure 2 shows the BB-FDR graphical model.
The beta prior is a departure from other two-groups exten-
sions, which use a flatter hierarchy and learn a predictive
model for ci (Scott et al., 2015; Tansey et al., 2017). We
found the flat approach to be difficult to train, leading to a
degenerate G that always predicts the global mean prior.
A hierarchical prior improves training for two reasons. First,
optimization is easier and more stable because the output of
the function is two soft-plus activations. Compared to a sig-
moid, this form leads to less saturated gradients. Second, the
additional hierarchy allows the model to assign different de-
grees of confidence to each experiment, changing the model
from homoskedastic to heteroskedastic. Finally, we found it
important to enforce concavity of the beta distribution; we
thus add 1 to both ai and bi.
We fit the model in (2) with stochastic gradient descent
(SGD) on an L2-regularized loss function,
minimize
θ∈R|θ|
−
∑
i
log pθ(zi) + λ ||Gθ(X)||2F , (4)
where ||·||F is the Frobenius norm. In pilot studies, we
found adding a small amount of L2-regularization prevented
over-fitting at virtually no cost to statistical power. For
computational purposes, we approximate the integral in (3)
by a fine-grained numerical grid.
Once the optimized parameters θˆ are chosen, we calculate
the posterior probability of each test statistic coming from
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the alternative,
wˆi = pθˆ(hi = 1|zi) (5)
=
∫ 1
0
cif1(zi)Beta(ci|Gθˆ,i(X))
cif1(zi) + (1− ci)f0(zi) dci .
Assuming the posteriors are accurate, rejecting the ith hy-
pothesis will produce 1− wˆi false positives in expectation.
Therefore we can maximize the total number of discoveries
by a simple step down procedure. First, we sort the posteri-
ors in descending order by the likelihood of the test statistics
being drawn from the alternative. We then reject the first q
hypotheses, where 0 ≤ q ≤ n is the largest possible index
such that the expected proportion of false discoveries is be-
low the FDR threshold. Formally, this procedure solves the
optimization problem,
maximize
q
q
subject to
∑q
i=1(1− wˆi)
q
≤ α ,
(6)
for a given FDR threshold α. By convention 00 = 0.
The model in (2)–(6) handles Stage 1 of the analysis. The
black box model G uses the entire feature vector Xi· of
every experiment to predict the prior parameters over ci.
The observations zi are then used to calculate the posterior
probability wˆi that the treatment had an effect. The selection
procedure in (6) uses these posteriors to reject a maximum
number of null hypotheses while conserving the FDR.
3.2. Stage 2: identifying important variables
Using a flexible black box model for G in (2) provides a
trade-off. On one hand, it enables BB-FDR to learn a rich
class of functions for the relationship between the covariates
and the test statistic. As we show in Section 4, this increases
power in Stage 1 compared to a standard linear model.
However, variable selection (Stage 2) is straightforward
in linear models whereas black box models are by defini-
tion opaque. Understanding which variables deep learning
models use to make predictions is an ongoing area of re-
search in both machine learning (e.g. Elenberg et al., 2017)
and specific scientific disciplines (e.g. Olden & Jackson,
2002; Giam & Olden, 2015, in ecology). As far as we are
aware, there are currently no methods that provide variable
selection with FDR control when the covariates may have
arbitrary dependency structure.
To overcome this challenge, BB-FDR uses conditional ran-
domization tests (CRTs) (Candes et al., 2018). The idea
of a CRT is to model each coordinate of the feature matrix
X·j using only the other coordinates X·−j . The conditional
distribution P(X·j |X·−j) then represents a valid null dis-
tribution for testing the hypothesis X·j ⊥ Z|X·−j , where
Z is the test statistic. The corresponding p-value can be
calculated by sampling from the conditional to approximate
the true p-value,
pj = EX˜·j∼P(X·j |X·−j)
[
I
[
t(z, X) ≤ t(z, (X˜·j , X·−j))
]]
,
where t is the test statistic of interest. Once the p-values
have been estimated for all features, we can apply standard
BH correction and report significant features.
BB-FDR tests which features are associated with a change in
the posterior probability of zi coming from the alternative.
It uses the negative entropy of the posteriors as the test
statistic,
t(z, X) =
∑
i
wˆi log wˆi +
∑
i
(1− wˆi) log(1− wˆi) . (7)
Intuitively, if a feature is useful in predicting treatment
efficacy, it should reduce the overall entropy of the posterior.
By definition, a feature sampled from the null adds no new
information to the model; it cannot systematically reduce
the entropy.
For this procedure to retain frequentist consistency guaran-
tees, both the conditional null distribution and the model
of the prior must be the true distributions. In practice, one
never has access to these and thus we estimate both; for the
conditional null, we use gradient boosting trees (Chen &
Guestrin, 2016).
4. Benchmarks
We perform a series of benchmark studies to assess the
performance of BB-FDR in both stages of inference. For
each benchmark, we compare the power of BB-FDR to
other state-of-the-art approaches. In all studies, we consider
binary covariates and real-valued z-scores as test statistics.
Across experiments, we found BB-FDR is particularly suit-
able for large samples: it outperforms competing methods
in both stages while being more computationally efficient.
4.1. Setup
We consider three different ground truth models for P (X),
the joint distribution over the covariates, and P (h = 1|X),
the prior probability of coming from the alternative distribu-
tion given the covariates:
• Constant: All covariates are sampled IID normal; the
prior is independent of the covariates, with P (hi =
1|X) = 0.5.
• Linear: Covariates are sampled from a multivariate
normal with full covariance matrix (i.e. conditionally
linear); the prior is a linear function with IID standard
normal coefficients for each covariate.
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Figure 3. The two alternative densities used in our benchmarks.
The well-separated (WS) density has little overlap with the null,
making for a stronger signal.
• Nonlinear: Covariates and prior coefficients are gen-
erated similarly. We first drawing 20 IID uniform
Bern(0.5) latent variables. For each covariate, 5 pairs
of latent variables (ui, uj) are chosen and with equal
probability are either ANDed or XORed together and
multiplied by a draw from a standard normal; the latent
weights are summed to get the final logit value for the
covariate or coefficient.
For each of the three ground truth models, we consider two
different alternative distributions:
• Well-Separated (WS): A 3-component Gaussian mix-
ture model, f1(z) = 0.48N (−2, 1) + 0.04N (0, 16) +
0.48N (2, 1)
• Poorly-Separated (PS): A single normal with high
overlap with the null, f1(z) = N (0, 9).
Figure 3 shows the densities used in our benchmarks.
For each of the 6 combinations of the above scenarios, we
run 100 independent trials. Each trial uses 50 covariates; for
all trials with a non-constant prior, 25 of the variables are
used in the true data generating distribution and the other
25 are null variables with no association with the outcome.
To measure sample efficiency, we also vary the sample size
from n = 100 to n = 50K. The target FDR threshold is set
to 10% for both stages of inference.
We compare BB-FDR to the classic Benjamini-Hochberg
(BH) method (Benjamini & Hochberg, 1995), the recently-
proposed NeuralFDR (Xia et al., 2017), and a fully-
Bayesian logistic regression model for ci in place of the
black box prior in (2). For NeuralFDR, we use the de-
fault recommended settings, including five random restarts
and a ten-layer deep neural network. The fully-Bayesian
method uses a standard normal prior on the weights and an
inverse-Wishart prior on the variance, with weak hyperpri-
ors. In the nonlinear scenario, we specify all possible pair-
wise interactions as the covariate set for the fully-Bayesian
model to ensure it is well-specified. We fit the model us-
ing Polya-gamma sampling (Polson et al., 2013) with 5000
burn-in iterations and 1000 samples. For BB-FDR, we use
a 50 × 200 × 200 × 2 network with ReLU activation; for
training we use RMS-prop (Tieleman & Hinton, 2012) with
dropout, learning rate 3× 10−4, and batch size 100, and run
for 50 epochs, with 3 folds to create 3 separate models as in
NeuralFDR; we set the λ regularization term to 10−4.
4.2. Stage 1 performance
Figure 4 shows the results for the Stage 1 benchmarks,
where the goal is to determine for which experiments the
treatment had an effect. The four methods generally con-
serve FDR at the specified 10% threshold, though Neu-
ralFDR seems to systematically violate FDR in the low-
sample regime.
Across all experiments, we see that both BH and NeuralFDR
under-perform the two Bayesian methods. In the case of
BH, this is straight-forward as it uses only the p-value from
each experiment and has no notion of side information. Neu-
ralFDR, on the other hand, uses a deep neural network and
several random restarts. There are a few possible reasons
for its poor performance. First, the NeuralFDR method
was reported to be very difficult to train by the original au-
thors, so it is possible that it is simply not finding good fits
of the model. Second, BB-FDR assumes that the alterna-
tive distribution is conditionally independent of the prior;
NeuralFDR makes no such assumption and may lose some
power as a result. Finally, NeuralFDR was originally tested
on 1- and 2-dimensional problems against relatively weak
baselines. Our benchmarks examine its performance in a
higher-dimensional setting and with several uninformative
features that may make fitting NeuralFDR difficult.
Since the fully-Bayesian method is well-specified in every
benchmark, it serves as an oracle model to establish a rea-
sonable upper bound on Stage 1 performance. However,
the oracle power depends on the MCMC approximation of
the posterior being well-mixed. As the sample size grows,
the empirical-Bayes model used by BB-FDR gains an in-
creasingly precise approximation to the true posterior. In
the large-sample regime with a well-separated alternative,
BB-FDR outperforms even the oracle. Furthermore, the
fully-Bayesian method takes several hours to fit in the non-
linear scenarios; BB-FDR fits within a few minutes and can
easily be run on a laptop.
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Figure 4. Hypothesis testing results on the synthetic datasets averaged over 100 trials at varying sample sizes on the two different
alternative distributions. Solid lines show power; dashed lines show estimated FDR; the red horizontal line denotes the specified 10%
FDR threshold. In general, the Benjamini-Hochberg and NeuralFDR methods have lower power since they do not model the alternative.
The fully-Bayesian method has high power in the low-to-moderate sample regime, but as the sample size grows the empirical-Bayes
approach of BB-FDR becomes more effective.
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Figure 5. Variable selection results at a 10% FDR threshold. In low sample regimes, the conditional null distribution used in the CRT
procedure is poorly fit and results in violated FDR thresholds. At moderate-to-large samples, BB-FDR has higher power than the
fully-Bayesian model and conserves FDR.
4.3. Stage 2 performance
Neither BH nor NeuralFDR provide support for detecting
important features (Stage 2), so we could not compare
against them. For the Bayesian linear regression, we take
the 90% posterior credible interval over the coefficient value
for each covariate. If the interval does not contain zero, we
reject the null hypothesis and report it as a discovered fea-
ture; this approach is standard in the Bayesian literature
(Gelman et al., 2014).
Figure 5 presents the results of the variable selection bench-
marks for the poorly-separated alternative distribution; re-
sults for the well-separated are similar. We omit the constant
scenario, since there are no features to discover. In the small
sample regime, the conditional distributions are poor esti-
mators of the conditional null distribution for each feature.
This leads to BB-FDR overestimating the number of signal
features and violating the FDR threshold. As the sample
size grows, the conditional null and black box prior become
more accurate, leading to FDR control and higher power,
respectively; in the large-sample regime, BB-FDR outper-
forms the fully-Bayesian approach.
We conclude by noting that BB-FDR is competitive with
the fully-Bayesian approach even when the latter is well-
specified. In practical data analysis scenarios, such as the
cancer study we discuss next, we do not know the true
prior function. It may easily contain many higher-order
interaction terms that are prohibitive to consider explicitly
in a fully-Bayesian model, making BB-FDR a pragmatic
choice for real-world scientific datasets.
5. Cancer drug screening
As a case study of how BB-FDR is useful in practice, we ap-
ply it to two high-throughput cancer drug screening studies
(Lapatinib and Nutlin-3) from the Genomics of Drug Sensi-
tivity in Cancer (GDSC) (Yang et al., 2012). For both drug
studies, BB-FDR increases the number of Stage 1 discover-
ies over classical BH correction; results on NeuralFDR were
similar to BH and are omitted. In Stage 2, BB-FDR discov-
ers biologically-plausible genes that may have a causal link
to drug sensitivity and resistance. Experimental details are
available in the supplement.
5.1. Analysis overview
Analysis of the two drug studies broadly follows the two
stages outlined in the motivating example in Section 1. The
Stage 1 task is to determine, for a specific drug being tested
on a specific cell line, whether the drug had any effect. As
with any biological process, natural variation injects ran-
domness at many levels of the experiment: how fast the cells
grow, how each cell responds, etc. Thus Stage 1 requires
performing statistical hypothesis testing to determine if the
cell population after treatment is truly smaller than would
be expected from a control (null) population.
The inferential goal in Stage 2 is to gain scientific insight
about which genes may be driving drug response. This
involves building a statistical model of the relationship be-
tween the genomic profile of a cell line and its corresponding
treatment response, then performing variable selection on
the model. The selected genes form the basis for potential
mechanisms of action and future experiments can be de-
signed to test for a causal link or to investigate new drugs
that better-target the proteins encoded by the genes.
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Lapatinib Nutlin-3
BRCA1, BRCA2, CDK4 P300, FLCN, FLT3
FGFR2, KIT, MSH2 MET, KIT, MSH6
SETD2, TP53, BCR-ABL
Table 1. Significant gene mutations identified by BB-FDR that are
associated with sensitivity and resistance to each drug. Both lists
align well with known genomic targets of Lapatinib and Nutlin-3.
5.2. Results
Figure 6 shows the aggregate number of treatment effects
discovered by both BH and BB-FDR. For both drugs, BB-
FDR provides approximately a 50% increase in Stage 1
discoveries compared to BH. The genomic profiles of the
cell lines provide enough prior information that even some
outcomes with a z-score above zero are still found to be
significant. This flexibility is impossible with classical Stage
1 testing methods like BH that do not consider covariate
information.
Table 1 lists the genes reported by BB-FDR in Stage 2.
Interpreting the quality of the results requires familiarity
with genomics and cancer biology. Below, we briefly detail
the scientific rational behind the biological plausibility of
the Stage 2 results and refer the reader to Weinberg (2013)
for a full review.
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Figure 6. Discoveries found by BB-FDR on the two drugs, com-
pared to the discoveries found by a naive BH approach. BB-FDR
leverages the genomic profiling information of the cell lines to
identify ≈ 50% more discoveries at the same 10% FDR threshold.
Lapatinib has been approved for the treatment of HER2-
positive breast cancers. BB-FDR indicates that BRCA1 and
BRCA2 are associated with responses to Lapatinib. Both are
tumor suppressor genes that are seen mutated in more than
10% of breast cancers (BRCA stands for “breast cancer”)
and thus cancer type may represent a latent confounder
for drug efficacy that induces a conditional dependence.
Lapatinib targets over-expression of the gene ERBB2 which
can be caused by a mutant CDK4 gene. FGFR2 and KIT
are also commonly associated with breast cancers (Slattery
et al., 2013; Zhu et al., 2014) and BRCA1 is known to
induce inactivation of the tumor suppressor MSH2 (Atalay
et al., 2002). Given Lapatinib’s success as a breast cancer
drug, the connection between all of the selected genes and
breast cancer is a reassuring sign that BB-FDR selected
biologically plausible features.
Nutlin-3 is an inhibitor of the oncogene MDM2, which
negatively-regulates TP53. When highly over-expressed,
MDM2 can functionally inactivate TP53. By targeting
MDM2, Nutlin-3 enables a non-mutated (“wild type”) TP53
to trigger apoptosis in cancer cells. However, if TP53 is
mutated, Nutlin-3 will be ineffective and hence its mutation
state is an important driver of Nutlin-3 sensitivity. When
wild type TP53 is present, MET controls the fate of the cell
(Sullivan et al., 2012), SETD2 functionality is required to
activate TP53 (Carvalho et al., 2014), P300 mediates TP53
acetylation (Reed & Quelle, 2014), and BCR-ABL is a gene
fusion that induces loss of TP53 (Pierce et al., 2000). These
genes interact in complex, non-linear ways, yet BB-FDR is
still able to identify them as important. Finally, FLCN is a
tumor suppressor gene that can delay cell cycle like TP53
(Laviolette et al., 2013). The mechanism by which FLCN
and TP53 are interrelated is currently unclear, representing
a potential target for future experiments.
6. Conclusion
We presented Black Box FDR (BB-FDR), an empirical-
Bayes method that increases statistical power in multi-
experiment scientific studies when side information is avail-
able for each experiment. BB-FDR combines deep prob-
abilistic modeling with recent multiple testing techniques
to boost testing power without sacrificing interpretability.
Benchmarks show that BB-FDR outperforms state-of-the-
art techniques, often substantially and under a wide array of
experimental conditions. BB-FDR also finds more experi-
mental discoveries two cancer drug screening datasets and
provides scientific insight into the mechanisms associated
with differential treatment response in cancer.
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Black Box FDR
A. Additional Stage 2 details and results
For BB-FDR, we fit an XGBoost (Chen & Guestrin, 2016)
model for each of the three folds and each of the 50 co-
variates. We used the XGBoost holdout predictions and
the corresponding BB-FDR fold-specific model to calculate
null posterior entropies. Each covariate p-value was esti-
mated based on 200 IID Monte Carlo draws and Benjamini-
Hochberg correction was applied to each set of 50 p-values
at a 10% FDR threshold.
As a practical matter, we recommend checking that estimat-
ing the global prior using the standard two-groups model
(Efron, 2008) provides a substantially lower number of dis-
coveries than BB-FDR. If it does not, then there is no clear
signal available in the covariates. If there is no clear benefit
to the added machinery of the black box modeling, then the
standard two-groups model should be sufficient.
Figure 7 shows the analogous results for the Stage 2 bench-
marks on the well-separated alternative distribution.
B. Experimental details for cancer drug
screening case study
We select two drugs in the GDSC dataset with known bio-
logical targets: Lapatinib, an EGFR-HERR2 inhibitor; and
Nutlin-3, an MDM2 inhibitor. The genomic targets of both
drugs are well understood, making them useful drugs on
which to validate BB-FDR. Each drug was tested on a large
number of cancer cell lines (294 for Lapatinib and 528 for
Nutlin-3) to determine treatment efficacy. The results were
measured by immunofluorescence; positive (untreated) and
negative (unpopulated) controls were decorrelated and tem-
poral batch effects were removed. Positive controls are
populations of cells which were never treated and thus their
measurements serve as a null distribution. We take the max-
imum concentration dosage for both drugs and calculate
z-scores for the treatment response, yielding a series of test
statistics.
Each cell line has also been profiled via WES and we fol-
lowed (Iorio et al., 2016) in filtering down to a set of relevant,
protein-changing gene mutations. We throw out any cell
lines that were not sequenced and any genes whose mutation
state was constant across all cell lines. For each cell line, we
then get a binary feature vector representing the genomic
profile of the experiment (66 features for Lapatinib and 71
for Nutlin-3). These features can then serve as an important
source of prior information for the sensitivity or resistance
of each cell line to the given drug.
A standard approach is to build a linear model of the ge-
nomic features to predict the outcome measurement. How-
ever, cellular processes are driven by complex, non-linear
interactions known as gene regulatory networks (Karlebach
& Shamir, 2008). A linear model of the interaction of genes
is unlikely to be well-specified and will likely be underpow-
ered, as in the non-linear prior scenario from Section 4.3.
BB-FDR is a natural fit given its flexibility to model highly
non-linear covariate dependencies.
We kept the majority of the BB-FDR settings the same as
in Section 4. However, to account for the smaller sample
sizes here, we changed the batch size to 10 and created 10
folds instead of 3 to maximize training data available to
each model.
For all of our results, we note that the Stage 2 discoveries
may be confounded by cancer cell type and do not nec-
essarily represent causal links. For instance, BRCA1 and
BRCA2 are frequently found mutated in breast cancer cells.
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Figure 7. Variable selection results at a 10% FDR threshold. Results are similar to that of the poorly-separated alternative in Section 4 of
the main text.
